TY - JOUR
T1 - Characterization of Acute Prescription Migraine Medication Use
T2 - Results From the CaMEO Study
AU - Hutchinson, Susan
AU - Lipton, Richard B.
AU - Ailani, Jessica
AU - Reed, Michael L.
AU - Fanning, Kristina M.
AU - Adams, Aubrey Manack
AU - Buse, Dawn C.
N1 - Funding Information:
Writing and editorial assistance was provided to the authors by Cory Hussar, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and was funded by Allergan plc , Dublin, Ireland. All authors meet the International Committee of Medical Journal Editors authorship criteria.
Funding Information:
Potential Competing Interests: This study was sponsored by Allergan plc, Dublin, Ireland. Writing and editorial assistance was provided to the authors by Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and was funded by Allergan plc. Neither honoraria nor other form of payments were made for authorship. Dr Hutchinson has served on advisory boards for Alder, Allergan, Amgen, Avanir, Biohaven, electroCore, Eli Lilly, Supernus, and Teva and is on the speakers bureau for Allergan, Amgen, Avanir, electroCore, Eli Lilly, Promius, Supernus, and Teva. Dr Lipton serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache; has received research support from the National Institutes of Health; receives support from the Migraine Research Foundation and the National Headache Foundation; has reviewed for the National Institute on Aging and National Institute of Neurological Disorders and Stroke; serves as consultant or advisory board member or has received honoraria from Alder, Allergan, Amgen, Autonomic Technologies, Avanir, Boston Scientific, Dr. Reddy's, electroCore, Eli Lilly, eNeura, GlaxoSmithKline, Merck, Novartis, Teva, and Vedanta; receives royalties from Wolff's Headache (8th edition, Oxford University Press) and Informa; and holds stock options in eNeura and Biohaven. Dr Ailani has served as a consultant for Alder, Allergan, Alpha Sites Consulting, Amgen, electroCore, Eli Lilly and Company, Impel, Promius, Satsuma, Teva; has been involved with continuing medical education (CME) programming with Avent (CME content and speaker's fee), Miller Communications (CME content and speaker's fee), and Peer View (CME speaker's fee); has been a speaker for Allergan, Avanir, Amgen, electroCore, Eli Lilly and Company, Promius, and Teva; has received grant support from the American Migraine Foundation, Allergan, and Biohaven; and provided editorial services to Current Pain and Headache Reports. Dr Reed is Managing Director of Vedanta Research, which has received research funding from Allergan, Amgen, Dr. Reddy's Laboratories, Eli Lilly, GlaxoSmithKline, Merck & Co, Inc, and Novartis via grants to the National Headache Foundation; Vedanta Research has received funding directly from Allergan for work on the CaMEO Study. Dr Fanning is an employee of Vedanta Research, which has received research funding from Allergan, Amgen, Dr. Reddy's Laboratories, Eli Lilly, GlaxoSmithKline, Merck & Co, Inc, and Novartis via grants to the National Headache Foundation; Vedanta Research has received funding directly from Allergan for work on the CaMEO Study. Dr Manack Adams is an employee of Allergan, plc. Dr Buse has received grant support and honoraria from Allergan, Avanir, Amgen, Biohaven, Eli Lilly and Company, and Promius and for work on the editorial board of Current Pain and Headache Reports.Writing and editorial assistance was provided to the authors by Cory Hussar, PhD, of Peloton Advantage, LLC, an OPEN Health company, Parsippany, NJ, and was funded by Allergan plc, Dublin, Ireland. All authors meet the International Committee of Medical Journal Editors authorship criteria.
Publisher Copyright:
© 2019 Mayo Foundation for Medical Education and Research
PY - 2020/4
Y1 - 2020/4
N2 - Objective: To characterize self-reported use of acute prescription medication for migraine in a sample representing the US population. Patients and Methods: Data were obtained from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. The CaMEO Study is an Internet-based cross-sectional longitudinal survey administered between September 17, 2012, and November 19, 2013. Demographic characteristics, migraine-related disability, symptom severity, quality of life, and psychiatric comorbidity profiles were evaluated. Results: Data from 13,624 respondents were analyzed, including 3121 (22.9%) self-reported current users of acute prescription medication for migraine, 1719 (12.6%) previous/discontinued users, and 8784 (64.5%) who had never used acute prescription medication for migraine. Mean ± SD monthly headache frequency was 7.3±7.1 days for current users, 5.6±6.6 days for those who discontinued, and 3.9±4.9 days for respondents who never used acute prescription medication for migraine. Current users experienced the highest degree of migraine-related disability based on Migraine Disability Assessment scores and the highest levels of migraine symptom severity based on Migraine Symptom Severity Scale scores. Current users also had the highest scores on the depression and anxiety questionnaires. The most commonly reported prescription medications used or “kept on hand” by current users were triptans (47.2%; 1474 of 3121), opioids (37.3%; 1164 of 3121), nonsteroidal anti-inflammatory drugs (31.9%; 997 of 3121), and barbiturates (12.8%; 399 of 3121), with many people reporting more than 1 medication. Conclusion: Despite reporting moderate to severe migraine-related disability and impairment, many people with migraine have never used acute prescription migraine medication. The burden related to migraine is great, especially among individuals currently using acute prescription medication for migraine.
AB - Objective: To characterize self-reported use of acute prescription medication for migraine in a sample representing the US population. Patients and Methods: Data were obtained from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. The CaMEO Study is an Internet-based cross-sectional longitudinal survey administered between September 17, 2012, and November 19, 2013. Demographic characteristics, migraine-related disability, symptom severity, quality of life, and psychiatric comorbidity profiles were evaluated. Results: Data from 13,624 respondents were analyzed, including 3121 (22.9%) self-reported current users of acute prescription medication for migraine, 1719 (12.6%) previous/discontinued users, and 8784 (64.5%) who had never used acute prescription medication for migraine. Mean ± SD monthly headache frequency was 7.3±7.1 days for current users, 5.6±6.6 days for those who discontinued, and 3.9±4.9 days for respondents who never used acute prescription medication for migraine. Current users experienced the highest degree of migraine-related disability based on Migraine Disability Assessment scores and the highest levels of migraine symptom severity based on Migraine Symptom Severity Scale scores. Current users also had the highest scores on the depression and anxiety questionnaires. The most commonly reported prescription medications used or “kept on hand” by current users were triptans (47.2%; 1474 of 3121), opioids (37.3%; 1164 of 3121), nonsteroidal anti-inflammatory drugs (31.9%; 997 of 3121), and barbiturates (12.8%; 399 of 3121), with many people reporting more than 1 medication. Conclusion: Despite reporting moderate to severe migraine-related disability and impairment, many people with migraine have never used acute prescription migraine medication. The burden related to migraine is great, especially among individuals currently using acute prescription medication for migraine.
UR - http://www.scopus.com/inward/record.url?scp=85081970944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081970944&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2019.11.025
DO - 10.1016/j.mayocp.2019.11.025
M3 - Article
C2 - 32247344
AN - SCOPUS:85081970944
SN - 0025-6196
VL - 95
SP - 709
EP - 718
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 4
ER -